ArticleAmerican journal of translational research2023
Comparison of clinical effects and costs among dabigatran etexilate, rivaroxaban and warfarin in elderly patients with atrial fibrillation.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.
- Effectiveness and Safety of Dose-Specific DOACs in Patients With Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.Cardiovascular therapeutics · 2025Pooled it
- Dabigatran outperforms warfarin in elderly patients with atrial fibrillation and stable coronary artery disease: reduced risks of bleeding and cardiovascular events.American journal of translational research · 2026Article
- Identification and Functional Investigation ofDiagnostics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the clinical effects and economic costs between Warfarin and novel oral anticoagulants in elderly patients with atrial fibrillation (AF).
methodsThis is a retrospective study. A total of 680 elderly AF patients receiving oral anticoagulants for the first time were selected as subjects and assigned into Group A, B and C. Patients in group A, B and C were given dabigatran etexilate, rivaroxaban and warfarin, respectively. Patients were followed up for 2 years. This study compared indicators of left ventricular diastolic function such as left ventricular posterior wall in end-diastole (LVPWd), minimum peak velocity in early diastole phase and maximum peak velocity in late diastole phase, indicators of myocardial ischemia including creatine kinase isoenzyme, lactate dehydrogenase (LDH) and myoglobin, as well as other outcomes including adverse events incidences and treatment costs, among the three groups.
resultsAfter treatment, LVPWd was found to be obviously lower in group A and group B than that in group C, while the minimum peak velocity in early diastole phase was markedly more in group A and B than that in group C (all P<0.05). In addition, the concentrations of myoglobin and LDH were significantly reduced in group A and B than those in group C (all P<0.05). The occurrence rate of adverse events was significantly lower in group A and B than that in group C (P<0.05). Moreover, treatment cost was markedly less in group A and B than that in group C (P<0.05).
conclusionCompared with warfarin, dabigatran etexilate and rivaroxaban not only have the ability to inhibit the myocardial ischemia indicators and improve left ventricular diastolic function while reducing the incidence of adverse events, but they also offer certain cost-effectiveness advantages for elderly patients with AF.
Indexed as
Identifiers
37303642PMC10251038W4380290998What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.